About this trial
To compare the effects of oxytocin and carbetocin, used as uterotonics in elective caesarean section surgeries, in terms of intraoperative hemodynamic changes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients scheduled for caesarean sections
Between 18-40 years
ASA I-II group
Those who will undergo general anesthesia
Disqualifiers
Those who prefer spinal or epidural anesthesia
Those who are outside the age range of 18-40
Those who are ASA III and above
Those with HT, DM, cardiac and respiratory diseases
Trial design
Parallel
Treatments tested in this trial
Group-C
Procedure/Surgery100 iu carbetosin administered to carbetocin group
Group-O
Procedure/SurgeryIn cesarean surgery, 5 IU of oxytocin will be administered after the baby delivered.
Treatment groups
Trial outcomes
Primary outcomes
Uterine tonus
The effect of carbetocin on uterine tone will be evaluated by the surgical team using a numerical scoring scale between 0-10. A score of 0 will indicate atony, and a score of 10 will indicate full contraction.
Additional uterotonic drug requirement
If the uterine tone is 7 or below, the surgical team will perform uterine massage, and in patients who do not see a sufficient increase in uterine tone, an additional uterotonic, 0.2 mg methylergonavine (Methyl ampoule 0.2 mg/ml) will be administered IM by the anesthesia team and recorded.
Secondary outcomes
Intraoperative bleeding
Total intraoperative bleeding was recorded by calculating and estimating the aspirator volume, pad-sponge-compress count and surgical area.
Mean Blood Pressure
Mean blood pressure will be measured every 5 minutes intraoperatively using a noninvasive method.
Heart Rate
Heart rate will be measured every 5 minutes intraoperatively using a noninvasive method.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.